73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Atossa Genetics Inc
Closed
0.62 6.9
Overview
Share price change
24h
Min
0.61
Max
0.62
Income | -269K -8.7M |
|---|---|
Employees | 15 |
EBITDA | -269K -8.7M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +904.76% upside |
Next Earnings | 24 Mar 2026 |
|---|
Market Cap | -23M 85M |
|---|---|
Previous open | -6.28 |
Previous close | 0.62 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Atossa Genetics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Atossa Genetics Inc Forecast
Price Target
By TipRanks
904.76% upside
12 Months Forecast
Average 6.33 USD 904.76%
High 8 USD
Low 4 USD
Based on 4 Wall Street analysts offering 12 month price targets forAtossa Genetics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Atossa Genetics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Live chat